Legal Landscape of Peptide Use in Sports

Where fat-loss peptides sit on WADA's list

If you compete in a sport that follows the World Anti-Doping Code, the question that matters is where a compound sits on WADA's Prohibited List. As of October 2026, the 2026 List is in force. Most peptides sold for fat loss are on it, prohibited at all times (in and out of competition). The prescription GLP-1 drugs semaglutide and tirzepatide are the exception: they are monitored, not banned. (For what the compounds themselves do, see our overview of fat-loss peptides.)

The list catches compounds in two ways. Some are named in a specific section, such as the growth hormone fragments in S2.2.3 or the growth hormone releasing factors in S2.2.4. Anything left over falls under S0, which bans any pharmacological substance not covered elsewhere that has "no current approval by any governmental regulatory health authority for human therapeutic use." That catch-all is why an unnamed research peptide is still a risk.

Guides that file semaglutide and tirzepatide under S4 (hormone and metabolic modulators) are wrong. Neither drug appears in any prohibited section of the 2026 List. The two GH fragments are a different story: both are named outright, which matters for anyone reading our page on HGH Fragment 176-191 and AOD-9604 with competition in mind.

WADA has published the 2027 List, which takes effect on January 1, 2027. According to USADA's athlete advisory, its S0 definition now names "peptides" among the examples of non-approved substances, next to drugs in development and designer drugs. USADA's list of peptides it considers prohibited names BPC-157 and AOD-9604 directly. It also lists ipamorelin and the GH-releasing peptides (GHRPs). Its warning is plain: a peptide that isn't named "may still be prohibited."

Semaglutide and tirzepatide: monitored, not banned

WADA's Monitoring Program covers substances that aren't prohibited but that accredited labs test for anyway, so WADA can learn how often athletes use them. The 2026 List's summary of changes clarifies that urine monitoring for semaglutide also covers tirzepatide. USADA confirms both stay in the 2027 Monitoring Program (in and out of competition).

For a tested athlete, that means a semaglutide or tirzepatide finding is not an anti-doping rule violation as of October 2026. No Therapeutic Use Exemption (TUE) is needed to use them.

Labs are still looking, though. Two 2026 papers describe urine tests built for this purpose. An Australian racing lab detected two semaglutide metabolites (U6 and U7) down to 50 picograms per millilitre (pg/mL). The Shanghai anti-doping lab gave one volunteer a single oral dose: the metabolites first showed up at 21 hours and were last seen at 28 hours, while breakdown products of the tablet's absorption enhancer stayed detectable for up to 7 days. Both groups point to weight-class sports such as wrestling and boxing as the reason for interest. WADA hasn't said whether the monitoring data will lead to a listing in a future year.

The legal question is separate from the sporting one. Semaglutide and tirzepatide are prescription medicines, and vials sold online as "research use only" are a different product. In August 2026, FDA sent warning letters to several peptide sellers. One letter covered a site whose catalog listed semaglutide and tesamorelin alongside retatrutide; FDA called them unapproved new drugs despite the research-use labels. Our page on whether peptides are legal covers that side. For an athlete, an unregulated vial adds a testing risk: if it contains anything prohibited, strict liability applies.

How testing finds peptides

Short peptides used to be a blind spot in drug testing. That has changed. A 2016 method from the Cologne anti-doping lab screens urine for more than a dozen small prohibited peptides in one run. It covers the GHRPs and ipamorelin as well as AOD-9604 and TB-500. Its detection limits (50-500 pg/mL) sit well below the 2 ng/mL minimum that WADA labs must reach, and the authors confirmed it on urine from people who had taken GHRP-2 or GHRP-6.

BPC-157 has its own test. In 2017, scientists at the Sports Medicine Research and Testing Laboratory in Salt Lake City reported finding it in confiscated vials. They showed it breaks down into a stable metabolite and validated a urine method with a detection limit of 0.1 ng/mL.

Published excretion data are thin for most research peptides, so clearance times quoted online are mostly guesses. Two Code rules make that guessing riskier. Labs can store samples and reanalyze them later with newer methods (Article 6.6). A case can also be brought up to 10 years after the violation (Article 17).

A positive test isn't the only route to a ban. The Code also treats use or attempted use (Article 2.2) and possession (Article 2.6) as violations in their own right, and these can be proven with other evidence.

Therapeutic Use Exemptions

A TUE lets an athlete use a prohibited substance for a documented medical reason. Under WADA's International Standard for Therapeutic Use Exemptions (2023 edition), the athlete must show that all of these conditions are met:

• A diagnosed medical condition backed by clinical evidence.
• No performance boost beyond a return to the athlete's normal health.
• The substance is an indicated treatment, and there's no reasonable permitted alternative.
• The need isn't a result of earlier prohibited use without a TUE.

National-level athletes apply to their national anti-doping organization. International-level athletes apply to their international federation.

Here's how that works out for fat-loss compounds as of October 2026:

• Semaglutide and tirzepatide: no TUE needed, because neither is prohibited. Getting them legally still takes a prescription.
• Tesamorelin: it's an FDA-approved drug, but only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its label says it isn't indicated for weight loss. An athlete with that diagnosis could apply. General fat loss wouldn't meet the "indicated treatment" test.
• AOD-9604, HGH Fragment 176-191, CJC-1295, ipamorelin and BPC-157: none is approved for any medical use, so there's no indication to point to. On the TUE criteria, an exemption for any of them looks very unlikely (our reading). The fat-loss evidence is also weak: no trial has measured fat loss, as our page on CJC-1295 and fat loss explains.

Sanctions

The Code runs on strict liability. In its own words, athletes "are responsible for any Prohibited Substance or its Metabolites or Markers found to be present in their Samples," and intent doesn't have to be shown. A mislabeled vial is not, on its own, a defense.

How long a ban runs depends partly on whether the substance is "Specified." The 2026 List makes every S0 substance Specified. Everything in S2 is non-Specified, and so is everything in S4.4. Under Article 10.2 of the 2021 Code, the version in force as of October 2026, the starting points look like this:

The athlete's results from the competition linked to the sample are also disqualified. The Code allows reductions when an athlete shows no significant fault, but the burden of proof sits with the athlete.

Pro leagues and the NCAA run their own testing rules, as do some strength federations. We didn't check those for this page, so look up your own organization's list.

What to watch next

• The 2027 List takes effect on January 1, 2027, with "peptides" named in S0.
• Semaglutide and tirzepatide stay in the Monitoring Program for 2027. Whether WADA will ever list them is an open question.
• Retatrutide is sold by research-peptide vendors (FDA's August 2026 letter named it) but isn't approved anywhere as of October 2026. If it is approved, S0 would no longer catch it automatically, and WADA would have to decide whether it belongs elsewhere on the list.